GSK: shares fall back after disappointing clinical study

(CercleFinance.com) - GSK shares lost ground on Wednesday morning on the London Stock Exchange following the pharmaceutical group's announcement of disappointing results from a clinical study on a herpes vaccine project.


At around 10:00 a.m. (local time), the shares were down 0.8%, one of the biggest declines on the FTSE 100 index, which was down 0.1% at the same time.

The company said this morning that the Phase I/II trial evaluating its experimental vaccine against herpes simplex virus (HSV) infections had failed to meet its primary endpoint.

Highly contagious, the herpes virus is responsible for the appearance of small, painful, fluid-filled lesions, notably on the mouth and lips (cold sores).

Following this failure, GSK has decided not to advance the project into a Phase III study, although it says it intends to look into its possible implications for the treatment of genital herpes.

Copyright (c) 2024 CercleFinance.com. All rights reserved.